1. Baseline characteristics of participants in the included studies.
| Study ID | Mean age (years)* | Male (%) | Current smoker (%) | Pre‐bronchodilator FEV1 L* | Significant bronchodilator reversibility (%) | CAT score | History of exacerbations prior to study entry (%) | Baseline eosinophil counts (cells/µL)* | Use of ICS at screening |
| Ferguson 2018 | 65.0 (7.7) | 70% | 41% | NR | 44% | 18.4 (6.3) | 25% | Counts NR (48% had blood eosinophils < 150 cells/µL) |
78% |
| Lipson 2018 | 65.3 (8.2) | 66% | 35% | 1.17 (0.47) | 18% (Significant reversibility cut‐off: ≥ 12% and ≥ 200 mL from baseline) |
20.1 (6.1) | 100% | Counts NR (43% had blood eosinophils < 150 cells/µL) |
72% |
| Papi 2018 | 64.4 (7.7) | 72% | 45% | 1.07 (0.31) | 33% (Significant reversibility cut‐off: > 12% from baseline) |
NR | 100% | 235 (200) | 65% |
| Rabe 2020 | 64.6 (7.6) | 60% | 41% | NR | 31% | 19.6 (6.6) | 100% | Counts NR, estimated median 167 | 80% |
*Data presented as mean (SD).
Abbreviations: CAT: Chronic Obstructive Pulmonary Disease Assessment Test; FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroids; NR: not reported; SD: standard deviation.